Parathyroid hormone is associated with prostate cancer

Area of Science:

• Endocrinology
• Urology
• Oncology

Background:

• Investigated the relationship between serum parathyroid hormone (PTH), vitamin D, and calcium levels and prostate cancer (CaP).
• Examined 459 patients (216 with CaP, 243 with benign prostate hyperplasia [BPH]) and 47 post-prostatectomy patients.
• Excluded patients with creatinine >1.4 mg/dl or parathyroid disease.

Purpose of the Study:

• To determine the association between serum PTH, vitamin D, and calcium levels and prostate cancer.
• To compare PTH levels in patients with CaP versus BPH.
• To analyze changes in PTH levels before and after radical prostatectomy.

Main Methods:

• Compared serum PTH, vitamin D, and calcium levels between CaP and BPH patient groups.
• Correlated serum parameters with clinical data in prostate cancer patients.
• Measured and compared preoperative and postoperative PTH levels in patients undergoing radical prostatectomy.

Main Results:

• Mean PTH levels were significantly higher in the CaP group (41.67 ± 28.82 pg/ml) compared to the BPH group (27.06 ± 17.32 pg/ml) (p < 0.001).
• No significant differences in PTH levels were observed based on prostate-specific antigen levels, Gleason score, or tumor stage.
• Postoperative PTH levels (26.93 ± 13.58 pg/ml) were significantly lower than preoperative levels (36.71 ± 21.04 pg/ml) in prostatectomy patients.

Conclusions:

• Serum PTH levels are elevated in patients with prostate cancer compared to those with benign prostate hyperplasia.
• Radical prostatectomy led to a significant decrease in serum PTH levels.
• These findings suggest a potential association between serum PTH and prostate cancer, warranting further investigation in larger cohorts.